Research has found New Zealand's burgeoning health-tech sector has significant economic potential but access to lucrative foreign markets is being slowed by hurdles in the earlier stages of development.
The health-tech sector generated an estimated $2.85 billion in revenue in just the last year - with record growth since Covid-19 struck.
But research from Callaghan Innovation has highlighted the key challenges for Kiwi healthtech businesses, including complicated clinical trial regimes, complex regulatory requirements, and difficulties accessing investment and educational support.
It's launched a programme to support the sector overcome these challenges and grow businesses. Kathryn speaks with Andrew Clews, the head of Health Technology at Callaghan Innovation and Garth Sutherland, chief executive of The Insides Company.